LON:HEMO

Hemogenyx Pharmaceuticals Interim Earnings Results & Report

Hemogenyx Pharmaceuticals logo
GBX 621 -69.50 (-10.07%)
As of 11:58 AM Eastern

Hemogenyx Pharmaceuticals reported Interim earnings on September 28, 2026. The company reported EPS of -GBX 101.70.

Earnings Announcement Details

Quarter
Interim
Time
Before Market Opens

Hemogenyx Pharmaceuticals EPS Results

Actual EPS
-GBX 101.70
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hemogenyx Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Hemogenyx Pharmaceuticals Interim Earnings FAQ

Hemogenyx Pharmaceuticals (LON:HEMO) reported earnings of -GBX 101.70 per share for Interim. The report was announced on Monday, September 28, 2026.

Hemogenyx Pharmaceuticals Earnings Headlines

Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Hemogenyx Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hemogenyx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hemogenyx Pharmaceuticals and other key companies, straight to your email.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals (LON:HEMO), a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

View Hemogenyx Pharmaceuticals Profile